Changing Face Of ‘Me Too’ Drugs On Display In 2014 NME Approvals
This article was originally published in Pharmaceutical Approvals Monthly
As the era of the primary care blockbusters waned, pharma R&D shifted toward less price-sensitive specialty fields. Now successful specialty drug development is producing its own sort of follow-on agents, and payers are pushing back. Even oncology is not immune.